The National Comprehensive Cancer Network® (NCCN®) revised its guidelines
G1 Therapeutics J-Code Announcement
October 1, 2021The National Comprehensive Cancer Network® (NCCN®) revised its guidelines—now Ribociclib (KISQALI®) is the only CDK4/6 inhibitor in combination with an AI designated as a Category 1 Preferred regimen in first-line HR+/HER2- mBC.1,2. For more information read Efficacy Across Trials | KISQALI® (ribociclib) | HCP (novartis.com)